SLCO1B1, CYP2C9 and Fluvastatin: SLCO1B1 Poor Function

No SLCO1B1 transporter function. Moderate risk of statin-induced myopathy with 80 mg based on SLCO1B1 alone.

Important Instructions: Please use CYP2C9 phenotype to select the appropriate recommendation below.

CYP2C9 Normal Metabolizer

Normal CYP2C9 enzyme activity. Normal response expected based on CYP2C9 alone.

Therapeutic Recommendation

  • Initiate ≤ 40 mg, if dose > 40 mg is needed, consider alternative statin or combination therapy.

CYP2C9 Intermediate Metabolizer

Decreased CYP2C9 enzyme activity. Potential for increased risk of myopathy based on CYP2C9 alone.

Therapeutic Recommendation

CYP2C9 Poor Metabolizer

Decreased CYP2C9 enzyme activity. Potential for increased risk of myopathy based on CYP2C9 alone.

Therapeutic Recommendation

Back to previous page